AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication

Nanna Monjé,Mihnea P. Dragomir,Bruno V. Sinn,Inga Hoffmann,Anuar Makhmut,Tincy Simon,Catarina A. Kunze,Jana Ihlow,Wolfgang D. Schmitt,Jonathan Pohl,Iris Piwonski,Sofya Marchenko,Carlotta Keunecke,Teodor G. Calina,Francesca Tiso,Hagen Kulbe,Caroline Kreuzinger,Dan Cacsire Castillo-Tong,Jalid Sehouli,Elena I. Braicu,Carsten Denkert,Silvia Darb-Esfahani,Kirsten Kübler,David Capper,Fabian Coscia,Markus Morkel,David Horst,Christine Sers,Eliane T. Taube

DOI: https://doi.org/10.1038/s41416-023-02550-1

IF: 9.075

2024-02-09

British Journal of Cancer

Abstract:Abstract Background The aim of this study was to analyse transcriptomic differences between primary and recurrent high-grade serous ovarian carcinoma (HGSOC) to identify prognostic biomarkers. Methods We analysed 19 paired primary and recurrent HGSOC samples using targeted RNA sequencing. We selected the best candidates using in silico survival and pathway analysis and validated the biomarkers using immunohistochemistry on a cohort of 44 paired samples, an additional cohort of 504 primary HGSOCs and explored their function. Results We identified 233 differential expressed genes. Twenty-three showed a significant prognostic value for PFS and OS in silico. Seven markers ( AHRR, COL5A2, FABP4, HMGCS2, ITGA5, SFRP2 and WNT9B ) were chosen for validation at the protein level. AHRR expression was higher in primary tumours ( p < 0.0001) and correlated with better patient survival ( p < 0.05). Stromal SFRP2 expression was higher in recurrent samples ( p = 0.009) and protein expression in primary tumours was associated with worse patient survival ( p = 0.022). In multivariate analysis, tumour AHRR and SFRP2 remained independent prognostic markers. In vitro studies supported the anti-tumorigenic role of AHRR and the oncogenic function of SFRP2. Conclusions Our results underline the relevance of AHRR and SFRP2 proteins in aryl-hydrocarbon receptor and Wnt-signalling, respectively, and might lead to establishing them as biomarkers in HGSOC.

oncology

What problem does this paper attempt to address?

The main purpose of this paper is to analyze the transcriptomic differences between primary and recurrent High-Grade Serous Ovarian Carcinoma (HGSOC) to identify biomarkers with prognostic significance.

The research background indicates that ovarian cancer is the fifth leading cause of cancer death among women in Western countries, with HGSOC being the most common histological subtype. It is often diagnosed at an advanced stage when the tumor has already spread within the abdominal cavity, resulting in a 5-year survival rate of only 43%, and approximately 80% of patients experience recurrence after initial treatment. To address this clinical challenge, researchers performed targeted RNA sequencing on 19 pairs of matched primary and recurrent HGSOC samples, identifying 233 differentially expressed genes. Through in vitro experiments, immunohistochemistry validation, and other methods, they further screened 7 candidate biomarkers (AHRR, COL5A2, FABP4, HMGCS2, ITGA5, SFRP2, and WNT9B).

The study results indicate that AHRR is highly expressed in primary tumors and is associated with better patient survival, while SFRP2 is highly expressed in the stroma of recurrent samples, and protein expression of SFRP2 in primary tumors is associated with poorer patient survival. Additionally, in multivariate analysis, tumor AHRR and SFRP2 remain independent prognostic markers. In vitro studies show that AHRR has anti-tumor effects, whereas SFRP2 has pro-tumor functions.

In summary, this study aims to identify molecules that can mark the progression from primary to recurrent HGSOC and evaluate their potential as prognostic markers, ultimately identifying AHRR and SFRP2 as two important prognostic markers.